Jones Trading reiterates Buy on ORIC Pharmaceuticals stock By Investing.com

Ipsen voluntarily withdrew Tazverik across all indications after Phase 3 SYMPHONY-1 reported secondary hematologic malignancies, creating downside risk for the EZH2 inhibitor space and pressure on peers. ORIC still trades up 71% over the past year at $12.08 (market cap $1.22B) and announced an at-the-market prospectus to sell up to $200M of common stock, while several analysts (Jones Trading, H.C. Wainwright, Oppenheimer) maintained or raised price targets (notably $25 and $15) and six analysts raised earnings estimates.

Analysis

The market reaction to a safety signal in the EZH2 class is being treated as a sector-wide de-risk event rather than an idiosyncratic hit — that amplifies volatility and forces re-pricing of probability-weighted outcomes across players with even tangential EZH2 exposure. Expect acquirers and strategic partners to re-calculate diligences: peak-sales multiples and late-stage probabilities will be cut, and contingent milestones in licensing deals will be renegotiated or deferred, disproportionately hurting firms reliant on single-asset valuation models.

Near-term mechanics that matter: equity overhang and funding cadence will dictate downside depth more than science in the next 1–3 months; conversely, independent positive readouts from non-EZH2 programs can re-ignite upside within 3–12 months because the market currently conflates class risk with program-level efficacy. Regulatory follow-up (label warnings, class reviews) typically takes quarters, not days — so the binary outcomes are stretched across a multi-quarter timeline and can create asymmetric entry points.

Operational second-order effects: CRO capacity, increased DSMB activity, and added pharmacovigilance spend will raise trial costs for smaller biotechs, compressing cash runways and making ATM sales or convertible financing likelier — that’s a buy-signal for activists and a sell-signal for risk-averse holders. Finally, sentiment-driven overshoots are common; technical liquidation by quant funds can push valuations to levels where upside from a clean 12–18 month catalytic readout becomes compelling versus downside capped by practical limits of dilution and regulatory remedies.

Key Decisions for Investors

• ORIC — Tactical long (1–2% portfolio): build in tranches over next 4–8 weeks via 12–18 month call options (target delta ~0.35–0.45) or outright equity if liquidity is needed. Risk: premium or share drawdown; Reward: ~50–100%+ if upcoming non-class catalysts validate programs within 6–12 months. Use a mental stop of 30–40% loss from entry or re-evaluate after any new financing announcement.
• ORIC — Put-protected buy (conservative): buy shares and simultaneously purchase 6–9 month OTM puts to cap downside while retaining upside to the next big readout. Timeframe: 3–9 months. Trade rationale: hedges dilution/near-term headline risk at the cost of financed insurance premium.
• Reallocate from momentum tech to event-driven biotech: shift 0.5–1% from high-beta SMCI/APP exposure into ORIC-sized positions to capture asymmetric event-driven upside. Timeframe: 3–12 months. R/R: sacrifice some convex tech upside for binary biotech upside tied to trial readouts.
• Income/volatility play for holders: if already long, sell 1–3 month covered calls to harvest premium during headline-driven chop, capping upside but generating yield. Size: keep written calls to no more than 25–33% of position to preserve upside optionality into catalysts.